SD-OCT pattern of retinal venous occlusion with cystoid macular edema treated with ozurdex ®

European Journal of Ophthalmology

Volumn 21, Issue 5, 2011, Pages 631-636

  Coscas, Gabriel ^a,b   Coscas, Florence ^a,b   Zucchiatti, Ilaria ^b   Glacet Bernard, Agnes ^a   Soubrane, Gisele ^a   Souïed, Eric ^a  

^a CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^b Centre Ophtalmologique de l'Odeon   (France)

Author keywords

Spectral domain optical coherence tomography

Indexed keywords

DEXAMETHASONE; RANIBIZUMAB;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BIOMICROSCOPY; BRANCH RETINA VEIN OCCLUSION; CATARACT; CENTRAL RETINA VEIN OCCLUSION; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EYE DISEASE; EYE PHOTOGRAPHY; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE; MALE; PHASE 3 CLINICAL TRIAL (TOPIC); PHOTORECEPTOR; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA MACULA CYSTOID EDEMA; RETINA VEIN OCCLUSION; SIDE EFFECT; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; SUSTAINED RELEASE FORMULATION; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL SYSTEM EXAMINATION;

AGED; AGED, 80 AND OVER; DEXAMETHASONE; DRUG IMPLANTS; FEMALE; FLUORESCEIN ANGIOGRAPHY; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETINAL VEIN OCCLUSION; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL ACUITY; VITREOUS BODY;

EID: 79960812927     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.5301/EJO.2011.7428     Document Type: Article

References (10)

1. Rogers S, McIntosh RL, Cheung N, et al, International Eye Disease Consortium. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 2010; 117: 313-9.
2. Coscas G, Dhermy P. Occlusions Veineuses Rétiniennes: Rapport de la Société Française d'Ophtalmologie. Paris: Masson éd, 1978; 196-207; 310-4.
3. Kohner EM, Laatikainen L, Oughton J. The management of central retinal vein occlusion. Ophthalmology 1983; 90: 484-7.
4. Hayreh SS. So-called "central retinal vein occlusion": II: venous stasis retinopathy. Ophthalmologica 1976; 172: 14-37.
5. Jonas JB, Kreissig I, Degenring RF. Intravitreal triamcinolone acetonide as treatment of macular edema in central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2002; 240: 782-3.
6. Park CH, Jaffe GJ, Fekrat S. Intravitreal triamcinolone acetonide in eyes with cystoid macular edema associated with central retinal vein occlusion. Am J Ophthalmol 2003; 136: 419-25.
7. Roth DB, Chieh J, Spirn MJ, Green SN, Yarian DL, Chaudhry NA. Noninfectious endophthalmitis associated with intravitreal triamcinolone injection. Arch Ophthalmol 2003; 121: 1279-82.
8. Ip MS, Scott IU, VanVeldhuisen PC, et al, SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol 2009; 127: 1101-14.
9. Scott IU, VanVeldhuisen PC, Oden NL, et al, SCORE Study Investigator Group. SCORE Study report 1: baseline associations between central retinal thickness and visual acuity in patients with retinal vein occlusion. Ophthalmology 2009; 116: 504-12.
10. Haller JA, Bandello F, Belfort R Jr, et al, Ozurdex Geneva Study Group. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010; 117: 1134-46.